Indonesia Bio Farma: Kexing  COVID-19 vaccine is 97% effective in early trials

Indonesia Bio Farma: Kexing  COVID-19 vaccine is 97% effective in early trials. According to Bloomberg news on December 8, according to an Indonesian company preparing to produce dosage forms locally, the COVID-19 vaccine developed by China Kexing Biological has shown up to 97% effectiveness in early trials.

Iwan Setiawan, director of corporate communications for Indonesian state-owned company PT Bio Farma, said that the effectiveness is based on preliminary data from a one-month clinical trial, and the final effectiveness will be determined in January.

Indonesian President Joko Widodo said on the 6th that he had received the first batch of 1.2 million doses of the new coronavirus vaccine from China, and he was “very grateful” for this. He expects to receive another 1.8 million doses of Chinese vaccine in early January next year.

“We are very grateful. Now that we have a vaccine, we can immediately contain the spread of the COVID-19 epidemic.”

Widodo revealed in a video that these vaccines came from China Kexing. After approval, large-scale vaccination will be carried out in Indonesia.

Disclaimer of medicaltrend.org